市場調查報告書

毛細胞白血病的全球市場:各治療方法、地理的成長率,趨勢及預測(2018年∼2023年)

Hairy Cell Leukemia Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 660532
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
毛細胞白血病的全球市場:各治療方法、地理的成長率,趨勢及預測(2018年∼2023年) Hairy Cell Leukemia Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

毛細胞白血病市場,預計從2018年到2023年的預測期間內,以5%的年複合成長率成長。毛細胞白血病,是異常的淋巴球的積蓄相關的血液癌症的一種。

本報告提供全球毛細胞白血病市場調查,整體市場趨勢,產品、各地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品與服務的威脅
    • 產業內的競爭

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 市場成長要素
    • 診斷率的上升
    • 老年人口的增加
  • 市場阻礙因素
    • 對於不重要的研究缺乏對症狀的認識
    • 地方醫院的有限的保健服務
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各治療法
    • 化療
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Biogenomics Limited
  • F. Hoffmann-La Roche AG
  • Incyte Corp.
  • Juno Therapeutics
  • MedImmune
  • Novartis
  • 其他

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 46197

Hairy cell leukemia is a very rare type of cancer, which accounts for approximately 2%, out of all the leukemia's. Hairy cell leukemia is characterized by the uncontrolled accumulation of lymphocytes by bone marrow. According to National Organization for Rare Disorders, approximately 600-800 new cases are diagnosed each year in the United States. Most of the affected individuals are males 50 years of age or older. Early diagnosis can help the patients live longer. In recent years, there are advanced diagnostic tests to detect the hairy cell leukemia. First and foremost diagnostic test is a complete blood profile which clearly indicates the total number of lymphocytes, which indicates the disease. Physicians can easily diagnose, if there is an enlarged spleen, by physical examination. One important confirmation test is presence of hairy cells in the blood in the lab tests. Most of the patients also require bone marrow biopsy for confirmation. Diagnosis rate of hairy cell leukaemia is increased during last two-three decades, which is expected to drives the market in the forecast period.

Key Market Trends

Chemotherapy Segment is Expected to Register a Significant Growth Over the Forecast Period

Based on therapy, it is segmented into chemotherapy and Targeted Therapy. The key factor contributing to the growth of the chemotherapy segment is the rising incidence of leukemia cases. According to the American Cancer Society estimates, there were around 22,840 death from leukemia in 2019. Many companies are focusing on developing breakthrough products for the treatment of hairy cell leukemia in order to maintain their competitive advantage and penetrate new regional markets. Chemotherapy drugs, specifically purine analogs such as cladribine and pentostatin, are considered as an initial treatment option for most individuals with hairy cell leukemia. Additionally, the increase in funding for companies involved in the research related to hairy cell leukemia is expected to boost the studied market.

North America holds the Largest Share in the Hairy Cell Leukemia Market

The hairy cell leukemia market holds the largest share in North America region due to the presence of high incidence rate, increase in geriatric population and advancements in the treatment of hairy cell leukaemia. According to National Organization for Rare Disorders, Hairy cell leukemia is a rare type of blood cancer, that affects about 6,000 persons in the United States. Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool and emerging economies in these regions.

Competitive Landscape

The hairy cell leukemia market is competitive and many of the global players are into the market. For instance - Amgen Inc, AstraZeneca plc, BioGenomics Limited, F. Hoffmann-La Roche Ltd, Incyte Corp, Johnson & Johnson, Merck KGaA, Merck & Co, Inc. and Pfizer Inc. are providing these products across the globe.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Leukemia Cases
    • 4.2.2 Increase in Diagnosis Rates
    • 4.2.3 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness
    • 4.3.2 Limited Health Services in Rural Hospitals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapy
    • 5.1.1 Chemotherapy
    • 5.1.2 Targeted Therapy
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 AstraZeneca plc
    • 6.1.3 BioGenomics Limited
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 Incyte Corp
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Merck KGaA
    • 6.1.8 Merck & Co, Inc.
    • 6.1.9 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS